CN101495115A - 组合治疗 - Google Patents

组合治疗 Download PDF

Info

Publication number
CN101495115A
CN101495115A CNA200780028588XA CN200780028588A CN101495115A CN 101495115 A CN101495115 A CN 101495115A CN A200780028588X A CNA200780028588X A CN A200780028588XA CN 200780028588 A CN200780028588 A CN 200780028588A CN 101495115 A CN101495115 A CN 101495115A
Authority
CN
China
Prior art keywords
pyridylmethyl
xylylenediamine
tetrahydro
bis
methyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CNA200780028588XA
Other languages
English (en)
Chinese (zh)
Inventor
G·布里杰
L·M·佩鲁斯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genzyme Corp
Original Assignee
Genzyme Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genzyme Corp filed Critical Genzyme Corp
Publication of CN101495115A publication Critical patent/CN101495115A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/401—Proline; Derivatives thereof, e.g. captopril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CNA200780028588XA 2006-08-02 2007-08-02 组合治疗 Pending CN101495115A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US83529006P 2006-08-02 2006-08-02
US60/835,290 2006-08-02

Publications (1)

Publication Number Publication Date
CN101495115A true CN101495115A (zh) 2009-07-29

Family

ID=38997866

Family Applications (1)

Application Number Title Priority Date Filing Date
CNA200780028588XA Pending CN101495115A (zh) 2006-08-02 2007-08-02 组合治疗

Country Status (12)

Country Link
US (1) US20100003224A1 (https=)
EP (1) EP2068868A2 (https=)
JP (1) JP2009545620A (https=)
CN (1) CN101495115A (https=)
AR (1) AR063470A1 (https=)
AU (1) AU2007281090A1 (https=)
BR (1) BRPI0714799A2 (https=)
CA (1) CA2659463A1 (https=)
IL (1) IL196556A0 (https=)
MX (1) MX2009001272A (https=)
RU (1) RU2009107030A (https=)
WO (1) WO2008017025A2 (https=)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107206085A (zh) * 2014-12-12 2017-09-26 联邦科学和工业研究组织 使用α 9 整联蛋白拮抗剂和CXCR4拮抗剂的HSC的迁移和释放
CN111712262A (zh) * 2017-12-06 2020-09-25 美真达治疗公司 用于动员造血干细胞和祖细胞的给药方案
CN115737821A (zh) * 2016-04-08 2023-03-07 赛罗斯制药有限公司 用于治疗aml和mds的rara激动剂

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004020462A1 (ja) 2002-08-27 2004-03-11 Fujii, Nobutaka Ｃｘｃｒ４拮抗薬およびその用途
CA2673719C (en) * 2006-12-21 2018-07-24 Biokine Therapeutics Ltd. T-140 peptide analogs having cxcr4 super-agonist activity for bone marrow recovery
US9427456B2 (en) 2009-06-14 2016-08-30 Biokine Therapeutics Ltd. Peptide therapy for increasing platelet levels
WO2012034194A1 (en) * 2010-09-17 2012-03-22 Antisense Therapeutics Ltd Method for mobilizing stem and/or progenitor cells
US9682078B2 (en) 2011-03-18 2017-06-20 University Of Virginia Patent Foundation Compositions and methods for tissue engineering and cell based therapies
RU2638802C2 (ru) 2011-05-16 2017-12-15 Джензим Корпорейшн Применение антагонистов cxcr4
WO2012174522A1 (en) * 2011-06-16 2012-12-20 Children's Medical Center Corporation Combined chemical modification of sphingosine-1-phosphate (s1p) and cxcr4 signalling pathways for hematopoietic stem cell (hsc) mobilization and engraftment
US9439942B2 (en) 2012-04-24 2016-09-13 Biokine Therapeutics Ltd. Peptides and use thereof in the treatment of large cell lung cancer
IL274572B2 (en) 2015-07-16 2024-01-01 Biolinerx Ltd Compositions and methods for treating cancer
CN109310733A (zh) 2016-02-23 2019-02-05 百欧林纳克斯有限公司 治疗急性骨髓性白血病的方法
WO2018085574A2 (en) * 2016-11-02 2018-05-11 Washington University Compositions comprising an integrin inhibitor and agents which interact with a chemokine and methods of use thereof
TWI734027B (zh) * 2017-09-18 2021-07-21 泰宗生物科技股份有限公司 用於治療癌症之組合物
US11260079B2 (en) 2017-12-06 2022-03-01 Magenta Therapeutics, Inc. Dosing regimens for the mobilization of hematopoietic stem and progenitor cells

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5021409A (en) * 1989-12-21 1991-06-04 Johnson Matthey Plc Antiviral cyclic polyamines
US6001826A (en) * 1989-12-21 1999-12-14 Anormed, Inc. Chemical compounds
GB9126677D0 (en) * 1991-12-16 1992-02-12 Johnson Matthey Plc Improvements in chemical compounds
DE69433301T2 (de) * 1993-06-08 2004-09-09 Smithkline Beecham Corp. Methoden zur erhöhung der biologischen aktivität von chemokinen
US6447766B1 (en) * 1993-06-08 2002-09-10 Smithkline Beecham Corporation Method of mobilizing hematopoietic stem cells
US5510332A (en) * 1994-07-07 1996-04-23 Texas Biotechnology Corporation Process to inhibit binding of the integrin α4 62 1 to VCAM-1 or fibronectin and linear peptides therefor
ATE180843T1 (de) * 1994-08-19 1999-06-15 Akzo Nobel Nv Zelluloselösungen und hieraus hergestellte produkte
US6506770B1 (en) * 1996-06-06 2003-01-14 Anormed, Inc. Antiviral compounds
US5968546A (en) * 1997-05-16 1999-10-19 Baur; Marcus Keratinocyte culture from precursor cells
HUP0102255A3 (en) * 1998-05-28 2001-12-28 Biogen Idec Ma Inc Cambridge Vla-4 inhibitor omepupa-v, pharmaceutical compositions comprising thereof and their use
US6365583B1 (en) * 1999-02-02 2002-04-02 Anormed, Inc. Methods to enhance white blood cell count
US6750348B1 (en) * 1999-03-24 2004-06-15 Anormed, Inc. Chemokine receptor binding heterocyclic compounds
GEP20053477B (en) * 1999-08-13 2005-03-25 Biogen Inc Cell Adhesion Inhibitors and Pharmaceutical Compositions Containing Them
DE60042030D1 (de) * 1999-12-17 2009-05-28 Genzyme Corp Chemokinrezeptor-bindende heterocyclische verbindungen
US6835731B2 (en) * 2000-09-15 2004-12-28 Anormed, Inc. Chemokine receptor binding heterocyclic compounds
PT1317451E (pt) * 2000-09-15 2006-12-29 Anormed Inc Compostos heterocíclicos que se ligam a receptores de quimioquinas
CA2419224A1 (en) * 2000-09-15 2002-03-21 Anormed Inc. Chemokine receptor binding heterocyclic compounds
AU2002211393B2 (en) * 2000-09-29 2007-06-28 Anormed Inc. Process for preparation of n-1 protected n ring nitrogen containing cyclic polyamines and products thereof
EP1613613B1 (en) * 2003-04-11 2021-06-02 Genzyme Corporation Cxcr4 chemokine receptor binding compounds
AU2004232361A1 (en) * 2003-04-22 2004-11-04 Anormed Inc. Chemokine receptor binding heterocyclic compounds with enhanced efficacy
US7501518B2 (en) * 2003-04-22 2009-03-10 Genzyme Corporation Methods of making 2,6-diaryl piperidine derivatives
EP1708703A4 (en) * 2003-12-11 2008-04-09 Anormed Inc CHEMOKIN RECEPTOR BINDING COMPOUNDS
CN1930127B (zh) * 2004-03-15 2012-11-21 阿诺麦德股份有限公司 用于合成cxcr4拮抗剂的方法
JP2008509928A (ja) * 2004-08-13 2008-04-03 アノーメド インコーポレイテッド 前駆／幹細胞を動員するためのケモカインの組み合わせ
US7825088B2 (en) * 2005-04-25 2010-11-02 The Cbr Institute For Biomedical Research, Inc. Methods for the treatment of multiple myeloma

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107206085A (zh) * 2014-12-12 2017-09-26 联邦科学和工业研究组织 使用α 9 整联蛋白拮抗剂和CXCR4拮抗剂的HSC的迁移和释放
CN107206085B (zh) * 2014-12-12 2022-01-28 联邦科学和工业研究组织 使用α9整联蛋白拮抗剂和CXCR4拮抗剂的HSC的迁移和释放
CN115737821A (zh) * 2016-04-08 2023-03-07 赛罗斯制药有限公司 用于治疗aml和mds的rara激动剂
CN115737821B (zh) * 2016-04-08 2024-04-12 赛罗斯制药有限公司 用于治疗aml和mds的rara激动剂
CN111712262A (zh) * 2017-12-06 2020-09-25 美真达治疗公司 用于动员造血干细胞和祖细胞的给药方案

Also Published As

Publication number Publication date
EP2068868A2 (en) 2009-06-17
WO2008017025A2 (en) 2008-02-07
WO2008017025A3 (en) 2008-10-09
JP2009545620A (ja) 2009-12-24
BRPI0714799A2 (pt) 2013-05-21
MX2009001272A (es) 2009-02-11
AU2007281090A1 (en) 2008-02-07
US20100003224A1 (en) 2010-01-07
IL196556A0 (en) 2009-11-18
RU2009107030A (ru) 2010-09-10
CA2659463A1 (en) 2008-02-07
AR063470A1 (es) 2009-01-28

Similar Documents

Publication Publication Date Title
CN101495115A (zh) 组合治疗
CN101500595A (zh) 组合治疗
KR100996378B1 (ko) 선조/줄기 세포를 이동시킴으로써 이식에 사용하기 위한 약제학적 조성물
CN101365336B (zh) 增强化疗的方法
JP2008509928A (ja) 前駆／幹細胞を動員するためのケモカインの組み合わせ
ES2497092T3 (es) Procedimientos para el aumento del flujo sanguíneo y/o la estimulación de la regeneración de tejidos
HK40026817A (en) Methods to mobilize progenitor/stem cells
MX2008002374A (en) Methods to enhancechemotherapy
MX2007001802A (en) Chemokine combinations to mobilize progenitor/stem cells

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication

Open date: 20090729